APO RESEARCH · REPORT
Crude Heparin
Heparin is one of the oldest drugs currently in widespread clinical use. It was originally isolated from canine liver cells. Heparin was discovered by Jay McLean and William Henry Howell in 1916.
Product & engineering
Understand the product.
Heparin is one of the oldest drugs currently in widespread clinical use. It was originally isolated from canine liver cells. Heparin was discovered by Jay McLean and William Henry Howell in 1916.
Heparin prevents the blood from clotting and is used to treat and prevent deep vein thrombosis and pulmonary embolism. It is also used as part of the treatment of myocardial infarction and unstable angina. Another application of heparin is an inner surface anticoagulant on various experimental and medical devices such as test tubes and renal dialysis machines.
Crude heparin is the starting material intended for further processing by FDA drug establishments into heparin sodium USP API (active pharmaceutical ingredient), not a finished drug product. The scope of this report is mainly about Crude Heparin, Crude heparin is the upstream raw material for heparin.
Selected research
Market Structure
Global Crude Heparin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
Heparin is one of the oldest drugs currently in widespread clinical use. It was originally isolated from canine liver cells. Heparin was discovered by Jay McLean and William Henry Howell in 1916.
Heparin prevents the blood from clotting and is used to treat and prevent deep vein thrombosis and pulmonary embolism. It is also used as part of the treatment of myocardial infarction and unstable angina. Another application of heparin is an inner surface anticoagulant on various experimental and medical devices such as test tubes and renal dialysis machines.
Crude heparin is the starting material intended for further processing by FDA drug establishments into heparin sodium USP API (active pharmaceutical ingredient), not a finished drug product. The scope of this report is mainly about Crude Heparin, Crude heparin is the upstream raw material for heparin.
Read the full market overview
The Top 5 manufacturers, Bioiberica, Shenzhen Hepalink, Nanjing King-friend, Sanofi and Fengrun Biological, held 56.28% of the market, in terms of revenue in 2019.
This report provides an overview of the global Crude Heparin market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Crude Heparin and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Crude Heparin sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Crude Heparin market size, projected growth trends, production technologies, key applications, and end-use industries.
Crude Heparin Segment by Company
Bioiberica
Shenzhen Hepalink
Sanofi
Nanjing King-friend
Fengrun Biological Technology
Aspen Oss
Hebei Changshan Biochemical
Changzhou Qianhong
Hepac (Darling Ingredients)
Huaian MDC Pharmaceutical
Yantai Dongcheng Biochemicals
Crude Heparin Segment by Type
Pig Intestine Mucosa Heparin
Bovine Heparin and Others
Crude Heparin Segment by Application
Unfractionated Heparin (UFH)
Low-Molecular-Weight Heparin (LMWH)
Crude Heparin Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Crude Heparin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Crude Heparin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Crude Heparin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Crude Heparin market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Crude Heparin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Crude Heparin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Crude Heparin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Pig Intestine Mucosa Heparin
- Bovine Heparin and Others
Applications
- Unfractionated Heparin (UFH)
- Low-Molecular-Weight Heparin (LMWH)
Companies covered
- Bioiberica
- Shenzhen Hepalink
- Sanofi
- Nanjing King-friend
- Fengrun Biological Technology
- Aspen Oss
- Hebei Changshan Biochemical
- Changzhou Qianhong
- Hepac (Darling Ingredients)
- Huaian MDC Pharmaceutical
- Yantai Dongcheng Biochemicals
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Crude Heparin Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Crude Heparin Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Crude Heparin Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Crude Heparin Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Crude Heparin Market Dynamics
- 2.1 Crude Heparin Industry Trends
- 2.2 Crude Heparin Industry Drivers
- 2.3 Crude Heparin Industry Opportunities and Challenges
- 2.4 Crude Heparin Industry Restraints
3 Crude Heparin Market by Manufacturers
- 3.1 Global Crude Heparin Revenue by Manufacturers (2021-2026)
- 3.2 Global Crude Heparin Sales by Manufacturers (2021-2026)
- 3.3 Global Crude Heparin Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Crude Heparin Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Crude Heparin Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Crude Heparin Manufacturers, Product Type & Application
- 3.7 Global Crude Heparin Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Crude Heparin Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Crude Heparin Players Market Share by Revenue in 2025
- 3.8.3 2025 Crude Heparin Tier 1, Tier 2, and Tier 3
4 Crude Heparin Market by Type
- 4.1 Crude Heparin Type Introduction
- 4.1.1 Pig Intestine Mucosa Heparin
- 4.1.2 Bovine Heparin and Others
- 4.2 Global Crude Heparin Sales by Type
- 4.2.1 Global Crude Heparin Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Crude Heparin Sales by Type (2021-2032)
- 4.2.3 Global Crude Heparin Sales Market Share by Type (2021-2032)
- 4.3 Global Crude Heparin Revenue by Type
- 4.3.1 Global Crude Heparin Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Crude Heparin Revenue by Type (2021-2032)
- 4.3.3 Global Crude Heparin Revenue Market Share by Type (2021-2032)
5 Crude Heparin Market by Application
- 5.1 Crude Heparin Application Introduction
- 5.1.1 Unfractionated Heparin (UFH)
- 5.1.2 Low-Molecular-Weight Heparin (LMWH)
- 5.2 Global Crude Heparin Sales by Application
- 5.2.1 Global Crude Heparin Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Crude Heparin Sales by Application (2021-2032)
- 5.2.3 Global Crude Heparin Sales Market Share by Application (2021-2032)
- 5.3 Global Crude Heparin Revenue by Application
- 5.3.1 Global Crude Heparin Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Crude Heparin Revenue by Application (2021-2032)
- 5.3.3 Global Crude Heparin Revenue Market Share by Application (2021-2032)
6 Global Crude Heparin Sales by Region
- 6.1 Global Crude Heparin Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Crude Heparin Sales by Region (2021-2032)
- 6.2.1 Global Crude Heparin Sales by Region (2021-2026)
- 6.2.2 Global Crude Heparin Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Crude Heparin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Crude Heparin Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Crude Heparin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Crude Heparin Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Crude Heparin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Crude Heparin Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Crude Heparin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Crude Heparin Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Crude Heparin Revenue by Region
- 7.1 Global Crude Heparin Revenue by Region
- 7.1.1 Global Crude Heparin Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Crude Heparin Revenue by Region (2021-2026)
- 7.1.3 Global Crude Heparin Revenue by Region (2027-2032)
- 7.1.4 Global Crude Heparin Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Crude Heparin Revenue (2021-2032)
- 7.2.2 North America Crude Heparin Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Crude Heparin Revenue (2021-2032)
- 7.3.2 Europe Crude Heparin Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Crude Heparin Revenue (2021-2032)
- 7.4.2 Asia-Pacific Crude Heparin Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Crude Heparin Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Crude Heparin Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Bioiberica
- 8.1.1 Bioiberica Company Information
- 8.1.2 Bioiberica Business Overview
- 8.1.3 Bioiberica Crude Heparin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Bioiberica Crude Heparin Product Portfolio
- 8.1.5 Bioiberica Recent Developments
- 8.2 Shenzhen Hepalink
- 8.2.1 Shenzhen Hepalink Company Information
- 8.2.2 Shenzhen Hepalink Business Overview
- 8.2.3 Shenzhen Hepalink Crude Heparin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Shenzhen Hepalink Crude Heparin Product Portfolio
- 8.2.5 Shenzhen Hepalink Recent Developments
- 8.3 Sanofi
- 8.3.1 Sanofi Company Information
- 8.3.2 Sanofi Business Overview
- 8.3.3 Sanofi Crude Heparin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Sanofi Crude Heparin Product Portfolio
- 8.3.5 Sanofi Recent Developments
- 8.4 Nanjing King-friend
- 8.4.1 Nanjing King-friend Company Information
- 8.4.2 Nanjing King-friend Business Overview
- 8.4.3 Nanjing King-friend Crude Heparin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Nanjing King-friend Crude Heparin Product Portfolio
- 8.4.5 Nanjing King-friend Recent Developments
- 8.5 Fengrun Biological Technology
- 8.5.1 Fengrun Biological Technology Company Information
- 8.5.2 Fengrun Biological Technology Business Overview
- 8.5.3 Fengrun Biological Technology Crude Heparin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Fengrun Biological Technology Crude Heparin Product Portfolio
- 8.5.5 Fengrun Biological Technology Recent Developments
- 8.6 Aspen Oss
- 8.6.1 Aspen Oss Company Information
- 8.6.2 Aspen Oss Business Overview
- 8.6.3 Aspen Oss Crude Heparin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Aspen Oss Crude Heparin Product Portfolio
- 8.6.5 Aspen Oss Recent Developments
- 8.7 Hebei Changshan Biochemical
- 8.7.1 Hebei Changshan Biochemical Company Information
- 8.7.2 Hebei Changshan Biochemical Business Overview
- 8.7.3 Hebei Changshan Biochemical Crude Heparin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Hebei Changshan Biochemical Crude Heparin Product Portfolio
- 8.7.5 Hebei Changshan Biochemical Recent Developments
- 8.8 Changzhou Qianhong
- 8.8.1 Changzhou Qianhong Company Information
- 8.8.2 Changzhou Qianhong Business Overview
- 8.8.3 Changzhou Qianhong Crude Heparin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Changzhou Qianhong Crude Heparin Product Portfolio
- 8.8.5 Changzhou Qianhong Recent Developments
- 8.9 Hepac (Darling Ingredients)
- 8.9.1 Hepac (Darling Ingredients) Company Information
- 8.9.2 Hepac (Darling Ingredients) Business Overview
- 8.9.3 Hepac (Darling Ingredients) Crude Heparin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Hepac (Darling Ingredients) Crude Heparin Product Portfolio
- 8.9.5 Hepac (Darling Ingredients) Recent Developments
- 8.10 Huaian MDC Pharmaceutical
- 8.10.1 Huaian MDC Pharmaceutical Company Information
- 8.10.2 Huaian MDC Pharmaceutical Business Overview
- 8.10.3 Huaian MDC Pharmaceutical Crude Heparin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Huaian MDC Pharmaceutical Crude Heparin Product Portfolio
- 8.10.5 Huaian MDC Pharmaceutical Recent Developments
- 8.11 Yantai Dongcheng Biochemicals
- 8.11.1 Yantai Dongcheng Biochemicals Company Information
- 8.11.2 Yantai Dongcheng Biochemicals Business Overview
- 8.11.3 Yantai Dongcheng Biochemicals Crude Heparin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 Yantai Dongcheng Biochemicals Crude Heparin Product Portfolio
- 8.11.5 Yantai Dongcheng Biochemicals Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Crude Heparin Value Chain Analysis
- 9.1.1 Crude Heparin Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Crude Heparin Production Mode & Process
- 9.2 Crude Heparin Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Crude Heparin Distributors
- 9.2.3 Crude Heparin Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst